Transcranial Magnetic Stimulation for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Transcranial Magnetic Stimulation for Health & Longevity

Created on 07/04/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

A non-invasive way of using magnetic pulses to change activity in targeted brain regions. Its strongest track record is lifting depression that resists standard medications, helping a meaningful share recover, though a return of symptoms within a year is common. Memory gains in mild decline are modest and often short-lived; benefits for otherwise healthy adults remain unproven. (Full Review)

Protocol

Standard Protocol
10 Hz, left DLPFC
120% resting motor threshold, ~3,000 pulses per session
Schedule
5 days/week, 4–6 weeks
About 20–30 sessions, typically followed by a taper
Time-Efficient Option
Theta-burst (iTBS)
~3-minute sessions, similar efficacy to standard rTMS
Time to effect
Depression
2–4 weeks
Gradual over daily sessions
Accelerated Protocols
Days
Multiple sessions per day compress the course
Cognitive Effects
Weeks
Where present, often short-lived

Benefits

Contraindications
  • Metal or electronic implants in or near the head (cochlear implants, deep brain stimulators, aneurysm clips, pulse generators)
  • Epilepsy or seizure within prior 12 months
  • History of status epilepticus
  • Significant or recent (~3 months) head trauma or stroke with cortical involvement
  • Increased intracranial pressure
  • Unstable bipolar disorder
  • Implanted cardiac devices with uncertain lead position
    •
Key Interactions
  • Seizure-threshold-lowering drugs (bupropion, tramadol, clozapine and other antipsychotics, theophylline, stimulants)
  • Sedating antihistamines (diphenhydramine) and high-dose caffeine products
  • Stimulant-type supplements (high-dose caffeine, synephrine, pre-workout blends)
  • Alcohol or benzodiazepine withdrawal states
  • Benzodiazepines and anticonvulsants
    •

Risk & Side Effects

  • High: Application-site pain and scalp discomfort; headache
    •
  • Medium: Seizure induction; vasovagal syncope and lightheadedness; transient hearing effects and tinnitus
    •
  • Low: Treatment-emergent mania or hypomania; facial twitching and jaw or neck pain
    •
  • Speculative: Unknown long-term effects of repeated courses; cumulative auditory exposure
    •

Monitoring

Marker Target Why
Resting motor threshold Stimulation at 80–120% of individually set value Calibrates a safe, effective dose and tracks cortical excitability
Depression rating (PHQ-9) Below 5 (remission range) Tracks mood response session to session
Depression rating (MADRS) Below 10 (remission range) Clinician-rated confirmation of mood change
Cognitive screen (MoCA) 26 or above out of 30 Detects change in memory and executive function
Thyroid-stimulating hormone ~0.5–2.5 mIU/L (functional) Excludes a thyroid-driven cause of low mood or slowed thinking
Vitamin B12 ~500–900 pg/mL (functional) Rules out a reversible cause of low mood and cognitive slowing

Cadence: Symptom rating scales weekly during the acute course; cognitive screen and mood scale at course end; reassessment every 3–6 months for those pursuing maintenance

Qualitative Assessment

  • Mood and interest: return of enjoyment and motivation in daily activities
  • Energy levels: sustained daytime energy rather than fatigue
  • Sleep quality: easier sleep onset and more restorative sleep
  • Cognitive clarity: subjective sharpness, focus, and word-finding
  • Daily function: ability to work, connect socially, and manage routines
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.